View Older Stories View More Recent Stories

May 30, 2017 08:30AM Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
May 4, 2017 05:00PM Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
May 2, 2017 04:02PM Gilead Sciences Announces Second Quarter 2017 Dividend
Apr 21, 2017 12:01PM Gilead Sciences (GILD) Says Scientific Presentations Showed Efficacy of Harvoni in Special Patient Populations With HCV Infection
Apr 21, 2017 12:00PM Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
Apr 21, 2017 05:48AM Gilead Sciences (GILD) Reports POC Data for GS-0976 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017
Apr 21, 2017 04:30AM Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Apr 20, 2017 12:00PM Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
Apr 20, 2017 09:30AM Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Apr 18, 2017 05:00PM Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
Apr 7, 2017 10:12AM Gilead Sciences (GILD) Announces FDA Approves New Indications for Harvoni and Sovaldi in Pediatric Patients 12 Years and Older with Chronic HCV
Apr 7, 2017 10:11AM U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection
Feb 28, 2017 05:00PM Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14
Feb 14, 2017 07:00PM Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
Feb 14, 2017 06:24AM Gilead (GILD) Announces Findings from Preclinical Study Evaluating HIV Capsid Inhibitors
Feb 14, 2017 06:22AM Gilead (GILD) Presents New Phase 2 Data on Combination of Bictegravir
Feb 13, 2017 06:45PM Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Feb 13, 2017 06:45PM Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Feb 8, 2017 05:00PM Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
Feb 8, 2017 07:28AM S&P 500 ekes out gain while banks drag on Dow
Feb 7, 2017 04:02PM Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Jan 24, 2017 05:00PM Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
Jan 20, 2017 05:51AM Gilead Sciences (GILD) MMA for Sofosbuvir/Velpatasvir/Voxilaprevir Full Validated in EU
Jan 20, 2017 05:48AM European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Jan 10, 2017 09:00AM Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Jan 3, 2017 04:30PM Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Dec 26, 2016 05:00PM Gilead Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9
Dec 19, 2016 02:03AM Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Vemlidy® for Patients With Chronic Hepatitis B Virus Infection
Dec 8, 2016 08:11AM Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir
Nov 16, 2016 05:00PM Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
Nov 16, 2016 04:17PM Gilead Sciences (GILD) Announces Momelotinib Phase 3 Met Primary Endpoint in Myelofibrosis; Secondary Endpoint Missed
Nov 16, 2016 04:15PM Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis
Nov 15, 2016 05:00PM Gilead Sciences to Present at the Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
Nov 14, 2016 04:32PM Gilead Sciences (GILD) Says Phase 2 Data for Selonsertib in NASH Presented at The Liver Meeting
Nov 14, 2016 04:30PM Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016
Nov 10, 2016 01:08PM Gilead Sciences' (GILD) Vemlidy Approved by FDA for Treatment of Chronic Hepatitis B
Nov 10, 2016 01:06PM U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
Nov 1, 2016 04:02PM Gilead Sciences Announces Fourth Quarter 2016 Dividend
Oct 25, 2016 05:00PM Gilead Sciences to Release Third Quarter 2016 Financial Results on Tuesday, November 1, 2016
Oct 24, 2016 05:00PM Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7
Oct 24, 2016 06:25AM Gilead Sciences (GILD) Announces Results from Studies of Switching HIV-1 Patients to Descovy; Results Statistically non-Inferior
Oct 24, 2016 06:24AM Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens
Oct 20, 2016 10:09AM Gilead Sciences (GILD) Announces Tipline Data from Four Sofosbuvir , Velpatasvir, Voxilaprevir Phase 3s in Genotype 1 - 6 HCV
Oct 20, 2016 10:07AM Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Ch
Oct 20, 2016 10:06AM Gilead Sciences (GILD) Announces Topline Selonsertib Phase 2 Data in NASH; Anti-Fibrotic Activity Noted
Oct 20, 2016 10:05AM Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD)
Sep 27, 2016 04:08PM Gilead Sciences (GILD), WHO Enter Five-Year Visceral Leishmaniasis Collaboration
Sep 27, 2016 04:05PM Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration
Sep 21, 2016 05:01PM Gilead (GILD) Terminates Phase 2/3 Study of GS-5745 in Ulcerative Colitis Due to Futility
Sep 21, 2016 05:00PM Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
View More Recent Stories View Older Stories